Get More Information on Growth Hormone Deficiency Market - Request Sample Report
The Growth hormone deficiency market Size was valued at USD 5.4 billion in 2023 and is expected to reach USD 8.5 billion by 2032 and grow at a CAGR of 5.0% over the forecast period 2024-2032.
Growth Hormone Deficiency Market: Expanding Horizons with Advancements and Increased Awareness
Market Growth Driven by Diagnostic Innovations and Rising Awareness
The Growth Hormone Deficiency (GHD) market is on a significant upward trajectory, propelled by advancements in diagnostic techniques, heightened awareness, and an expansion of treatment options. The increasing recognition of GHD’s profound impact on health, combined with ongoing research and development, underscores the market's promising future.
Growth hormone deficiency is prevalent in approximately 2 to 3 individuals per 10,000 people, according to an NCBI article from May 2022. This condition results from structural issues in the pituitary gland, such as pituitary adenomas and craniopharyngiomas, accounting for about 57% of cases. Childhood-onset GHD, often congenital, affects growth throughout a person's life and is associated with comorbidities including obesity, diabetes, hypertension, and cardiovascular diseases. The rising prevalence of these associated conditions is driving demand for effective GHD treatments.
A major factor driving the growth of the GHD market is the increase in cases due to genetic disorders, trauma, and medical therapies. Approximately 1 in 4,000 to 10,000 people is affected by GHD, with conditions arising either in infancy or later in childhood. Early diagnosis and treatment are crucial for achieving normal height and improving overall health outcomes.
Additionally, the aging population is a key driver for growth hormone treatments. Research shows that growth hormone levels decline with age, with over 30% of the elderly experiencing levels below the normal range. By age 55, growth hormone secretion drops significantly from peak levels seen during puberty. The World Health Organization projects that the global population aged 60 and above will increase from 12% to 22% between 2015 and 2050, further boosting the demand for growth hormone therapies.
Market key players are also accelerating growth. For example, in February 2022, OPKO and Pfizer received EU marketing approval for their Once-Weekly NGENLA (somatrogon) Injection, reflecting progress in treatment options. Early detection and intervention for related endocrine disorders are crucial for better management and prevention of severe complications, driving both market growth and research in this field.
Overall, the GHD market is expanding due to increasing prevalence, heightened awareness, and advancements in treatment and diagnostics.
Market Dynamics
Drivers
Advances in Diagnosis, Awareness, and Lifestyle Factors
The Growth Hormone Deficiency (GHD) market is experiencing notable growth due to several key drivers. Despite GHD being relatively rare, with only about 1 in 4,000 to 10,000 children and 1 in 10,000 adults diagnosed, its profound impact emphasizes the need for early and accurate diagnosis and effective treatment.
A major driver of the market is enhanced diagnostic capabilities. Traditionally, diagnosing GHD involved labor-intensive stimulation tests, where chemicals were injected to prompt the pituitary gland to release growth hormone. These methods were cumbersome and prone to inaccuracies. However, advancements in imaging technology, particularly magnetic resonance imaging (MRI), have significantly improved diagnostic precision. MRI scans are now essential for detecting pituitary gland abnormalities or tumors that can cause GHD.
Increased awareness of GHD is another critical driver of market growth. Awareness campaigns and educational initiatives have led to better symptom recognition and a greater understanding of the condition among healthcare providers and patients. This heightened awareness has resulted in more cases being identified and treated.
Lifestyle factors also contribute to the rising incidence of GHD. Modern lifestyle changes, such as increased stress, poor sleep patterns, and fluctuating glucose levels, can impact endocrine function and hormone secretion. These factors are believed to contribute to the growing number of GHD diagnoses, further driving demand for effective growth hormone therapies.
Overall, these drivers—enhanced diagnostic methods, increased awareness, and lifestyle factors—are crucial in shaping the GHD market, leading to more accurate diagnoses and improved patient outcomes.
Pursuing Advanced Treatments for Growth Hormone Deficiency (GHD) to Enhance Growth Potential, Body Composition, and Overall Health
Restraints
High Costs of Synthetic Growth Hormone Therapy Hinder Access and Management of Growth Hormone Deficiency (GHD)
Growth hormone deficiency (GHD) significantly impacts growth, development, body composition, energy levels, and overall well-being, with somatropin therapy proving effective. However, the high cost of synthetic growth hormone therapy remains a major constraint on the GHD market, limiting patient access and optimal management of the condition.
The high costs associated with GHD therapy stem from the complex and costly process of creating synthetic growth hormones. Pharmaceutical companies face substantial R&D expenses and must recoup these investments through sales. Producing recombinant human growth hormone requires specialized facilities, highly purified materials, and rigorous quality control, all contributing to elevated production costs. Consequently, many patients struggle to afford the medication, even with insurance coverage. This financial barrier impedes the wider adoption of effective GHD treatments and highlights the need for more affordable therapeutic options.
Key Market Segmentation
By Brand
Norditropin: Manufactured by Novo Nordisk, Norditropin emerged as the dominant player in 2023, commanding the largest market share valued at USD 1.6 billion. This brand is anticipated to maintain its dominance, growing at a significant compound annual growth rate (CAGR) of 4.9% from 2024 to 2032. Norditropin’s market leadership is driven by Novo Nordisk’s strong brand reputation and history of producing high-quality medical products. The product’s efficacy in treating growth hormone deficiency, supported by extensive clinical research, adds to its competitive edge. Norditropin's preloaded pen system, which is premixed and prefilled, offers convenience by eliminating manual mixing, making it a preferred choice among patients.
Genotropin: Ranking as the second-largest player, Genotropin held a revenue share of 25% and a market size of USD 1.4 billion in 2023. It is projected to grow to USD 2.1 billion by 2032. Genotropin is a synthetic form of human growth hormone (HGH) used to treat growth hormone deficiencies, including conditions like Turner syndrome and Prader-Willi syndrome. However, it is not recommended for patients with certain severe conditions.
By Application
Idiopathic Short Stature (ISS): Dominated the GHD market with a 45% share, the ISS segment generated USD 2.5 billion in revenue in 2023 and is projected to reach USD 3.8 billion by 2032, growing at a CAGR of 4.8%. ISS, characterized by shorter-than-average height without a known cause, is gaining attention due to heightened awareness about its impact on physical and psychological health. Approximately 60-80% of children with short stature globally are classified as ISS, presenting a significant growth opportunity.
Pediatric Growth Hormone Deficiency: Holding a 30% market share, this segment generated USD 1.5 billion in revenue in 2023 and is expected to grow at the fastest CAGR of 5.3% from 2024 to 2032. Pediatric GHD, an endocrine disorder causing inadequate growth hormone secretion, can lead to stunted growth and related health issues if untreated. Increased awareness, early diagnosis, and improved diagnostic capabilities drive this segment’s rapid growth.
By End-User
Hospital Pharmacies: Led the GHD market, this segment commanded a substantial 48% share and generated USD 2.7 billion in revenue in 2023. It is projected to grow at a CAGR of 4.8% from 2024 to 2032. Hospital pharmacies play a crucial role as recombinant growth hormone medications are prescription drugs requiring physician approval. Many hospitals require patients to obtain prescribed medications directly from in-house pharmacies to ensure proper medication management and adherence to healthcare standards.
Specialty Pharmacies: Holding the second-largest share, this segment contributed 35% to the end-user market, generating USD 1.7 billion in revenue in 2023. It is expected to grow at the fastest CAGR of 5.3% during the forecast period. Specialty pharmacies focus on medications for complex or chronic conditions requiring specialized handling and care. They provide additional services such as patient education and adherence programs, enhancing patient outcomes and contributing to market growth.
REGIONAL ANALYSIS:
North America: Dominated the GHD market, North America held a 40% market share, contributing USD 2.2 billion in revenue in 2023. The region is expected to grow to USD 3.3 billion by 2032. North America's dominance is driven by high healthcare expenditure, strong demand for growth hormone therapies, advanced research and development, and the presence of major pharmaceutical companies like Pfizer Inc. and Eli Lilly and Company. Comprehensive healthcare systems, favorable reimbursement policies, and high awareness levels further bolster the market in this region.
Europe: Holding the second-largest share of the GHD market with 27%, Europe generated USD 2.1 billion in revenue in 2023, projected to rise significantly by 2032. Growth in Europe is fueled by increasing incidences of GHD, rising healthcare expenditure, and government investments in healthcare. The European Medicines Agency reported a prevalence rate of 4.7 per 10,000 people in 2023, underscoring the region's need for effective GHD treatments.
Asia-Pacific: The fastest-growing market, Asia-Pacific expanded at a CAGR of 5.3% from 2024 to 2032. Contributing USD 0.9 billion in 2023 and projected to reach USD 1.4 billion, this region benefits from increasing healthcare investments, a large patient base, and rising awareness of growth hormone therapies. Economic growth and improved access to advanced medical treatments are key drivers of market expansion in Asia-Pacific
Need any customization research on Growth Hormone Deficiency Market - Enquiry Now
Eli Lilly and Company, ROCHE (Genentech, Inc.), Ferring B.V, Pfizer Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Novartis AG, Merck Kga, Anhui Anke Biotechnology Group Co., Ltd, EMD Serono Inc, and others.
Recent Developments
Novo Nordisk expanded its clinical trials for Norditropin, focusing on its effectiveness in treating idiopathic short stature (ISS). The company reported promising preliminary results indicating improved growth outcomes in pediatric patients.
June 2023: Pfizer announced the launch of a new formulation of its growth hormone therapy, Genotropin, designed to improve patient adherence. The new formulation includes an advanced delivery system that simplifies administration and minimizes discomfort.
May 2022: Eli Lilly received FDA approval for its new growth hormone therapy, Zomacton, which features a novel, extended-release mechanism. This new treatment aims to provide more stable hormone levels with fewer injections required, enhancing patient convenience.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 5.4 Billion |
| Market Size by 2032 | US$ 8.5 Billion |
| CAGR | CAGR of 5.0% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope & Others) • By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader–Willi Syndrome, Small for Gestational Age & Others) • By End-User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy & Specialty Pharmacy) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles |
Eli Lilly and Company, ROCHE (Genentech, Inc.), Ferring B.V, Pfizer Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Novartis AG, Merck Kga, Anhui Anke Biotechnology Group Co., Ltd, EMD Serono Inc, and others. |
| Key Drivers | • Growing awareness about growth hormone deficiency (GHD) and its treatments are the key drivers of this market. • The increasing prevalence of GHD is a key factor rationale for the growth in market size. |
| RESTRAINTS | • The side effects of synthetic growth hormone therapy are restraining the market. • High Price of Growth Hormone Replacement Therapy (GHD) is Restraining the overall market. |
Ans: Growth Hormone Deficiency Market Size was valued at USD 5.4 billion in 2023.
Ans: The Growth Hormone Deficiency Market is to grow at a CAGR of 5.0% over the forecast period 2024-2032.
Ans: North America region is dominating the Growth Hormone Deficiency Market.
The increased number of FDA approvals is also offering an opportunity for important businesses to create novel medications with fewer adverse effects.
Increase in the number of R&D activities.
Ans: The major players are Eli Lilly and Company, Roche, Ipsen, Ferring B.V., Novo Nordisk A/S, Pfizer, Inc, Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Novartis AG, Merck KGaA, and others.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Growth Hormone Deficiency Market Segmentation, by Brand
7.1 Chapter Overview
7.2 Norditropin
7.2.1 Norditropin Market Trends Analysis (2020-2032)
7.2.2 Norditropin Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Genotropin
7.3.1 Genotropin Market Trends Analysis (2020-2032)
7.3.2 Genotropin Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Humatrope
7.4.1 Humatrope Market Trends Analysis (2020-2032)
7.4.2 Humatrope Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Saizen
7.5.1 Saizen Market Trends Analysis (2020-2032)
7.5.2 Saizen Market Size Estimates and Forecasts to 2032 (USD Million)
7.6 Omnitrope
7.6.1 Omnitrope Market Trends Analysis (2020-2032)
7.6.2 Omnitrope Market Size Estimates and Forecasts to 2032 (USD Million)
7.7 Others
7.7.1 Others Market Trends Analysis (2020-2032)
7.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
8. Growth Hormone Deficiency Market Segmentation, by Application
8.1 Chapter Overview
8.2 Growth Hormone Deficiency
8.2.1 Growth Hormone Deficiency Market Trends Analysis (2020-2032)
8.2.2 Growth Hormone Deficiency Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Turner Syndrome
8.3.1 Turner Syndrome Market Trends Analysis (2020-2032)
8.3.2 Turner Syndrome Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Idiopathic Short Stature
8.4.1 Idiopathic Short Stature Market Trends Analysis (2020-2032)
8.4.2 Idiopathic Short Stature Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Prader–Willi Syndrome
8.5.1 Prader–Willi Syndrome Market Trends Analysis (2020-2032)
8.5.2 Prader–Willi Syndrome Market Size Estimates and Forecasts to 2032 (USD Million)
8.6 Small for Gestational Age
8.6.1 Small for Gestational Age Market Trends Analysis (2020-2032)
8.6.2 Small for Gestational Age Market Size Estimates and Forecasts to 2032 (USD Million)
8.7 Others
8.7.1 Others Market Trends Analysis (2020-2032)
8.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Growth Hormone Deficiency Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospital Pharmacy
9.2.1 Hospital Pharmacy Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacy Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Retail Pharmacy
9.3.1 Retail Pharmacy Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Online Pharmacy
9.4.1 Online Pharmacy Market Trends Analysis (2020-2032)
9.4.2 Online Pharmacy Market Size Estimates and Forecasts to 2032 (USD Million)
9.5 Specialty Pharmacy
9.5.1 Specialty Pharmacy Market Trends Analysis (2020-2032)
9.5.2 Specialty Pharmacy Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Growth Hormone Deficiency Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.2.4 North America Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.5 North America Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.2.6.2 USA Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.6.3 USA Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.2.7.2 Canada Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.7.3 Canada Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.2.8.2 Mexico Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.8.3 Mexico Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.1.6.2 Poland Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.6.3 Poland Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.1.7.2 Romania Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.7.3 Romania Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.1.8.2 Hungary Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.8.3 Hungary Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.1.9.2 Turkey Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.9.3 Turkey Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.4 Western Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.5 Western Europe Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.6.2 Germany Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.6.3 Germany Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.7.2 France Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.7.3 France Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.8.2 UK Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.8.3 UK Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.9.2 Italy Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.9.3 Italy Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.10.2 Spain Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.10.3 Spain Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.13.2 Austria Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.13.3 Austria Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Growth Hormone Deficiency Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.4 Asia Pacific Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.5 Asia Pacific Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.6.2 China Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.6.3 China Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.7.2 India Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.7.3 India Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.8.2 Japan Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.8.3 Japan Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.9.2 South Korea Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.9.3 South Korea Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.10.2 Vietnam Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.10.3 Vietnam Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.11.2 Singapore Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.11.3 Singapore Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.12.2 Australia Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.12.3 Australia Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Growth Hormone Deficiency Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.1.4 Middle East Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.5 Middle East Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.1.6.2 UAE Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.6.3 UAE Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.1.7.2 Egypt Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.7.3 Egypt Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.1.9.2 Qatar Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.9.3 Qatar Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Growth Hormone Deficiency Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.2.4 Africa Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.5 Africa Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.2.6.2 South Africa Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.6.3 South Africa Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Growth Hormone Deficiency Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.6.4 Latin America Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.5 Latin America Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.6.6.2 Brazil Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.6.3 Brazil Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.6.7.2 Argentina Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.7.3 Argentina Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.6.8.2 Colombia Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.8.3 Colombia Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Growth Hormone Deficiency Market Estimates and Forecasts, by Brand (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Growth Hormone Deficiency Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Growth Hormone Deficiency Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11. Company Profiles
11.1 Eli Lilly and Company
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 ROCHE (Genentech, Inc.)
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Ferring B.V
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Pfizer Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 Novo Nordisk A/S
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 Teva Pharmaceutical Industries Ltd
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Novartis AG
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 Merck Kga
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 Anhui Anke Biotechnology Group Co., Ltd
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 EMD Serono Inc
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Brand
Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
Others
By Application
Growth Hormone Deficiency
Turner Syndrome
Idiopathic Short Stature
Prader–Willi Syndrome
Small for Gestational Age
Others
By End-User
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Specialty Pharmacy
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Bioremediation Market size was estimated at USD 14.95 billion in 2023 and is expected to reach USD 34.27 billion by 2032 with a growing CAGR of 9.69% during the forecast period of 2024-2032.
The Microfluidics Market was valued at USD 27.86 billion in 2023 and is expected to reach USD 92.43 billion by 2032, growing at a CAGR of 14.29% from 2024-2032.
The Dentures Market was valued USD 1.62 Billion in 2023 and estimated to reach USD 3.00 Billion by 2032 at compound annual growth rate 7.10% during the forecast period 2024-2032.
The Robotic Surgical Procedures Market size was USD 11.69 Billion in 2023 and is expected to reach USD 56.26 Billion by 2031 and grow at a CAGR of 21.7% over the forecast period of 2024-2031.
The Artificial Intelligence in Ultrasound Imaging Market size was valued at $889.1 Mn in 2023 and is expected to reach $2047.7 Mn by 2032 and grow at a CAGR of 8.7% over the global forecast period of 2024-2032.
The Antimicrobial Resistance Surveillance Market was valued at USD 5.90 Billion in 2023 and is projected to grow to USD 9.50 billion by 2032 with a CAGR of 5.47% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
